Ein Gefängnis ohne HCV-Infektion Utopie oder Realität

Professor Michael Levy Australian National University, Canberra

Hepatitis C

- > At least 6 genetic variants, which respond to specific treatments differently
- Genotype 3 may carry a higher probability of developing hepatic cell carcinoma
- > DAAs curative, high therapeutic profile; truly short treatment
- Sofosbuvir marketed in the US in 2013
- Pre-cirrhotic treatment is critical
- Pre-treatment assessment of cirrhosis is essential
- Post-treatment surveillance is critical, NOT ONLY IF cirrhosis was present pre-treatment; remember the enduring risks of re-infection

Hepatitis C

- Abdominal ultrasound necessary only if cirrhosis or a space occupying lesion are a possibility
- Fibroscan useful when the chance of cirrhosis is medium (< 35 years of age, the risk of cirrhosis is low)
- AST to platelet ratio (APRI) is sufficient instead of fibroscan, especially in younger patients (i.e prisoners)

Hepatitis C in Australia

- Australian Government has committed \$1 billion for HCV treatment irrespective of severity of disease, including prisoners; "silent" on retreatment of reinfection
- 5-year agreement with pharmaceutical industry, from 1 March 2016
- A 12 week, curative course of treatment costs ~\$110,000

Hepatitis C in Australia

- There were ~233,000 Australians infected with hepatitis C, ~9,000 new infections annually prior to 2016
- Prior to March 2016, <3,000 were receiving treatment (annually); interferonbased treatments were unpopular, selective and cure was not guaranteed
- Between March 2016 and July 2017, nearly 22,500 Australians received treatment (~1,000 were prisoners)

Hepatitis C in Australian Prisons

Treatment should occur in a setting where re-infection is minimised.

- How can this be achieved in prison?
- Bring your contacts for treatment (snow-ball recruitment within networks)
- Re-treat reinfection (\$100,000 per episode ??)
- Continue to re-test, post-treatment.

Hepatitis C in Australian Prisons

- People who inject drugs are transmitters of HCV
- Prisoners are amplifiers of transmission as prisons are 'world class' needle exchanges {NOT}
- Is re-infection a problem?

Australian Prisons

- Cost free to the prisoner-patient
- Public health v clinical need
- Snow-ball recruitment by 'the treated'
- The final stage toward elimination
- The enduring fractures in the chain of transmission





The testing programme for hepatitis C has indentified 107 infections in 95 people, since the AMC was commissioned. (February 2017)

- 22 are considered to be in-custody transmissions
- 41 are considered 'indeterminate' as to environment of transmission (either custody or community), and
- 44 were determined as in-community infections.

2010 - prevalence of HCV Ab - 48% (presumed PCR positivity ~35%)

11

Interferon treatment offered, but poor uptake

3rd generation treatment - very poor results

March (actually April) 2016 - DAA treatments commenced

October 2016 - 20% PCR positive

August 2017 - 3% PCR positive

With access to Direct Acting Anti-viral treatments for hepatitis C infection, we have developed:

- A nurse lead model of care
- Supported by pharmacy
- Access to specialist care for complex cases (extremely rare), and
- A small group of doctors, familiar with the authorisation process.

18/10/2017

13

"Extreme" cases:

18/10/2017

14

Since 1 March 2016:

- 113 treatment authorities obtained
- 2 patients did not have a 12 week sustained viral response 1 was a reinfection, the 2nd ???
- 2 patients released to freedom before End of Treatment
- ~\$A6,000,000 estimated Rx costs
- PCR prevalence reduced from 30% to 3%! In just less than 18 months.

Treating Hepatitis C in Prison

BENEFITS

- Proximity of the health service to the patient
- Support from mental health, close at hand
- "Shared Care" is tailored to the environment efficiency
- Supervision of every dose compliance, side-effects
- Peer support
- Alcohol is reasonably well controlled
- Access to pharmacotherapies but not in all jurisdictions
- Less 'chaos' benefits individuals with poorer social function (sic: compliance)
- Aboriginal incarceration, cannot be ignored

Treating Hepatitis C in Prison

RISKS

- Access to the full range of harm minimisation strategies is limited
- Re-infection is a real risk
- Side-effects of treatment in a closed environment, .. too easily 'punished'
- Transition to community / loss to follow-up
- Will DAAs find a "price" in the prison-drug market?

Hepatitis C in Australian Prisons

1 visit -> treatment

- ► The future of fibroscan; escorts to appointments
- Sterilised environment by when, how maintained?
- Treat 40/1000 for 15 years will halve prevalence is this acceptable?

Issues for Consideration

- HCV prevalence
- HCV incidence
- Transmission oh no!!!!
- Treatment access who is in, who is out?
- Treatment compliance do all doses need to be supervised?

18/10/2017

19

- "These treatments are side-effect free" oh no!!
- Therapeutic prevention v harm minimisation

Issues for Consideration


- Is HCV elimination possible? Without treating prisoners?
- Drug prices a shackle, or?
- Screening policies opt-in, opt-out, targeted (on risk disclosure, or)

18/10/2017

20

What is the "market price" of a DAA tablet in prison?

Canberra Times - 26 August 2012



... and what about that Needle Exchange?

- Government commitment
- Australian Medical Association and the Public Health Association of Australia support
- Mixed support from detainees
- Muted support from Non-Government Organizations
- Mixed messages from the Canberra Times
- Vehement opposition from prison officers

18/10/2017

Hepatitis C in Australian Prisons

Early access to these medications has already raised some interesting issues for prisoner health services:

- Harm minimisation implementation in Australian prisons will be reassessed by custodial authorities, utilising a limited evidence base and an existing flawed paradigm; and
- Hepatitis C will continue to reveal strengths and weaknesses in the Australian health/ corrective services interface.

